PanMediso Holdings achieves breakthrough in core production technology for medical isotope Ac-225

image caption: PanMediso Holdings Team from left to right:Academician Robin Grimes, Chair of the Joint Technical Committee, Academician Andrew Carlick，CEO UK side, Mr. Leo Dang, CEO China side, Mr. Ivan Fu, Chairman of the Board of Directors

PanMediso Holdings (Shenzhen) Limited, announced a breakthrough in the key production technology for the medical isotope Ac-225. PanMediso Holdings is a leading global enterprise in the research, production, and sale of medical isotopes Ac-225 and Ge-68. The company's first phase focuses on addressing the technological and capacity bottlenecks associated with the long-term reliance on imported medical isotopes in China, aiming for realizing the full process flow of Ac-225 and Ge-68 in China.

Ac-225 has demonstrated excellent therapeutic effects in clinical research and treatment applications. It has been shown to improve patient survival rates and treatment efficacy while reducing side effects, and lowers medical costs. As one of the most promising and highly anticipated medical isotopes, it is in high demand globally. PanMediso Holdings' recent development may be a step towards bridging the supply gap, and will effectively support further exploration of new cancer treatments.

Academician Andrew Carlick, Co-Founder of PanMediso Holdings, and Director & CEO on UK side, stated, "The cyclotron-based Ac-225 technology employed by PanMediso Holdings is highly mature and has been validated by institutions. As the result of our years of wisdom and resources, it features the advantages such as high purity, high yield, low radiation, and minimal raw material loss, and will play a significant role in cancer treatment. With the combined efforts of our international team, we will continue to advance nuclear medicine technology."

Mr. Leo Dang, Co-Founder of PanMediso Holdings, and Director & CEO on China side, commented, "PanMediso Holdings will continue to focus on technological and process innovations and plans to further expand the application fields of medical isotopes such as Ac-225 and Ge-68. We aim to provide a comprehensive solution from raw materials to finished products, from research to scaling, and to commercial-level production. We are building a complete technological platform for nuclear medicine, covering isotope production, core equipment research and development, nuclear drug RXO, next-gen diagnostic devices and AI+TAT. While intensifying our research and development strength for radiopharmaceuticals, we keep advancing the clinical translation and application of world-leading technologies, contributing PanMediso Holdings Power to scientific research and healthcare."